Researchers at SRI are developing a new Multiple Sclerosis drug that can be taken by mouth. It will be more convenient than current treatments, which require frequent hospital visits for injections or intravenous infusions.
SRI Biosciences is developing a long-lasting, two-part microbicide gel to protect women from HIV and HSV infections—and the delivery system puts the technology in the hands of women themselves.
